Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Category: News

News

Morfeas Koumas awarded a FENS/IBRO-PERC Fellowship for advanced training in Barcelona

No Comments
| News

We are delighted to announce that our first-year Ph.D. student, Morfeas Koumas (BSc, MSc), has been awarded the FENS/IBRO-PERC Fellowship to conduct a six-week research exchange at the University of Barcelona. Morfeas will train under the mentorship of Dr. Jordi Bonaventura, an expert in addiction neuroscience and behavioral pharmacology. This fellowship represents a crucial step […]

Read More »

Dr. Andria Michael presents research on ketamine-based therapies for opioid relapse prevention

No Comments
| News

Dr. Andria Michael, a postdoctoral researcher in the Zanos Lab, recently represented our laboratory at the 13th International Multithematic Scientific Bio-Medical Congress in Cyprus, at the European University Cyprus School of Medicine. Her presentation highlighted groundbreaking work on novel pharmacotherapies for preventing relapse to opioid use disorders during abstinence. The research focuses on ketamine, a […]

Read More »

New pre-print: VirTarget framework reveals how Multiple Sclerosis immunotherapies engage with Epstein-Barr Virus-driven disease mechanisms

No Comments
| News

The AI & Systems Bioinformatics Unit of the Translational Neuropharmacology Lab has released a new preprint introducing VirTarget, the first virus-informed pharmacogenomics framework designed to systematically evaluate how multiple sclerosis (MS) immunotherapies interact with Epstein-Barr virus (EBV)-driven pathogenesis. While EBV is increasingly recognized as a central driver of MS, current immunotherapies are prescribed without considering […]

Read More »

New preprint: VirTrack framework reveals stage-specific EBV pathogenesis in Multiple Sclerosis

No Comments
| News

We’re excited to share our latest preprint, “VirTrack: A Framework for Inferring Viral Influence on Disease-Associated Transcriptomes — Clinical Type-Specific Epstein–Barr Virus Pathogenesis in Multiple Sclerosis,” now available on bioRxiv. This work, led by Dr. Anna Onisiforou, Head of our AI & Systems Bioinformatics Unit, represents a major advance in understanding how Epstein–Barr virus (EBV) […]

Read More »

Translational Neuropharmacology Lab presents on novel therapies for brain disorders

No Comments
| News

Dr. Panos Zanos recently delivered a presentation on novel pharmacological therapies for brain diseases at the Ierokipio University in Paphos, Cyprus. The Ierokipio University is a lifelong learning initiative that brings scientific knowledge to the general public, fostering dialogue between researchers and community members on important health and medical topics. The presentation provided an overview […]

Read More »

Dr. Zanos was invited and presented on antidepressant mechanisms of action of ketamine and other rapid-acting antidepressants at the 6th German-Cypriot Psychotherapy Conference

No Comments
| News

Dr. Panos Zanos delivered an invited presentation at the 6th German-Cypriot Conference Psychotherapy Dialogues, titled “Neurobiology of Depression: Traditional & Rapid-acting Pharmacotherapies.” The presentation addressed a critical challenge in psychiatry: conventional antidepressants require three to four weeks to produce therapeutic effects, with approximately thirty percent of patients failing to respond. Dr. Zanos explored the neurobiological […]

Read More »

Featured in Nature Mental Health: Advancing ketamine research and brain pathology treatments

No Comments
| News

We are happy to share that Dr. Zanos, the Director of the Translational Neuropharmacology Lab, was recently featured in a Q&A article published by Nature Mental Health. The discussion explores our laboratory’s pioneering work on ketamine and its metabolites as novel treatments for brain pathologies, with particular emphasis on depression and substance use disorders. The […]

Read More »

Researchers from the Zanos lab attend the European Researchers’ Night 2025

No Comments
| News

We are pleased to share that the Translational Neuropharmacology Lab participated in the European Researchers’ Night (ERN) 2025, held on September 26, 2025, at the Cyprus State Fair in Nicosia. This annual event, organized by the Research and Innovation Foundation, brings research and innovation closer to the public through interactive demonstrations and activities. Our team […]

Read More »

Dr. Zanos has been recognized among world’s top 2% of scientists in the 2024 Stanford University database

No Comments
| News

We are pleased to announce that Dr. Zanos, Director of the Translational Neuropharmacology Lab, has been included in the Stanford University database of the world’s top 2% scientists, published by Elsevier. This prestigious recognition places Dr. Zanos among an elite group of researchers globally and reflects the significant impact of our laboratory’s research contributions to […]

Read More »

Zanos Lab research featured in the Cypriot “Politis” Newspaper

No Comments
| News

Our Master’s student and registered pharmacist, Georgios Kousathanas, was recently featured in the Cypriot “Politis” newspaper discussing one of our research topics on ketamine as an antidepressant treatment. The article, titled “Ketamine as a Model Drug for Rapid Antidepressant Action”, covers a part of the work being conducted in our laboratory on ketamine’s rapid-acting therapeutic […]

Read More »

Posts pagination

Previous 1 2 3 4 … 13 Next

Recent Posts

  • Research spotlight: Unraveling the role of Eukaryotic Elongation Factor 2 Kinase in the antidepressant mechanism of (2R,6R)-hydroxynorketamine June 4, 2026
  • Research spotlight: Alexithymia and emotion regulation across smoking status groups May 26, 2026
  • New manuscript: The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein–Barr Virus–Linked Disease? March 12, 2026
  • New Preprint article – From Heatwaves to Brainwaves: Climate-Driven Microplastics Promote Epstein–Barr Virus Reactivation and Female-Biased Risk for Alzheimer’s Disease and Multiple Sclerosis February 24, 2026
  • New Publication – Linking Misophonia and Tinnitus: Common and Divergent Neurobiological Mechanisms January 29, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress